Scientists test 'Living Drug' to fight advanced cancers
NCT ID NCT06478251
Summary
This is a very early-stage study testing a new type of personalized treatment for people with advanced solid tumors. Doctors will collect a patient's own immune cells, genetically modify them to target a specific cancer mutation (KRAS G12V or G12D), and infuse them back into the body. The main goals are to find a safe dose and see if this approach shows any signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University school of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.